3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
28
Lymphoma
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Breast Neoplasms
22
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Carcinoma, Non-Small-Cell Lung
21
Lymphoma, Non-Hodgkin
19
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hodgkin Disease
15
Lymphoma, T-Cell, Cutaneous
13
Glioblastoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Brain Neoplasms
12
Recurrence
11
Myelodysplastic Syndromes
11
Mycosis Fungoides
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Burkitt Lymphoma
11
Neuroblastoma
10
Neoplasms
10
Sezary Syndrome
9
Congenital Abnormalities
9
Prostatic Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Squamous Cell Carcinoma of Head and Neck
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms, Plasma Cell
7
Interventions
Cisplatin
6
pembrolizumab
5
fludarabine
5
Nivolumab
5
Cyclophosphamide
5
aldesleukin
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ifosfamide
4
Radiotherapy
3
Ipilimumab
3
fludarabine phosphate
2
entinostat
2
cabozantinib
2
avelumab
2
aflibercept
2
Specimen Handling
2
CTLA-4 Antigen
2
Adoptive Transfer
2
vinflunine
1
toripalimab
1
rocakinogene sifuplasmid
1
ripretinib
1
oncogene protein E7, Human papillomavirus type 16
1
niraparib
1
nimotuzumab
1
lenvatinib
1
enfortumab vedotin
1
durvalumab
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Penile Neoplasms
×
Vorinostat
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled